July 30, 2010 By:William Looney
To shed some light on China's potential, Pharm Exec sat down with Peter Young, President and Managing Partner of Young & Partners, who recently met with government and industry officials to review the investment and M&A climate for medicines.
 |
July 8, 2010 By:William Looney
As Europe sets the pace in slashing drug prices to meet austerity goals industry is seeking fresh ways to control the fallout. Will more dialogue be enough?
 |
June 30, 2010 By:John Smith, Dodge Communications
Survey suggests now is the time for biotechs to bolster communications in a highly charged acquisition atmosphere.
 |
December 9, 2009 By:John Gardner
The rules of the game have changed. While pharmaceutical executives have been busy trying to keep up with a radically shifting marketing landscape, technology has swept in and changed everything marketers held sacred.
 |
 | December 8, 2009 By:Alexandra Kibble
Alexandra Kibble of Thomson Reuters identifies the products and therapy areas to watch next year.
 |
November 18, 2009 By:Emmanuel Le Poul
Allosteric modulators are an emerging class of orally available small molecule drugs that may have multiple advantages compared to traditional drugs.
 |
October 28, 2009 By:Benjamin Curtis
Google opened up a whole new era of social media when it released Sidewiki - a tool that allows anyone to comment on any Web site. Now pharma has a new battle to fight.
 |
October 21, 2009
Industry Audit and Company of The year.
 |
 | October 19, 2009
Pharm Exec interviews some of this year's emerging leaders to learn their strategies for success.
 |
|